金城医药：与Giskit公司ExEm® Foam商业化权益谈判尚未有最新进展，与中国药科大学就黄体酮长效注射液项目开展合作

Core Viewpoint - The company is in negotiations for exclusive commercialization rights of ExEm Foam in China, which is used for evaluating tubal patency in women with infertility [1] Group 1 - The company confirmed ongoing negotiations with Giskit Pharma B.V. regarding ExEm Foam's exclusive commercialization rights in China, but there are no recent updates on the progress [1] - The company is collaborating with China Pharmaceutical University to develop long-acting formulations for drugs related to reproductive health and women's diseases, specifically focusing on a progesterone long-acting injection project [1] - The company will announce any necessary disclosures regarding these matters in a timely manner [1]